Skip to main content

Table 5 Blood products and reversal agents

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

  Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
PCC (units), [median (IQR)] 2100 (1800-2400) 2000 (1700–3000) 2100 (1800-2400) 0.346
ECs given 48 (13.9) 15 (20.3) 33 (12.1) 0.073
Number of ECs
 1 23 (6.7) 6 (8.2) 17 (6.2)  
 2 14 (4.1) 3 (4.1) 11 (4.0)  
 3 7 (2.0) 4 (5.5) 3 (1.1)  
 4 2 (0.6) 2 (2.7) 0 (0.0)  
 5 2 (0.6) 0 (0.0) 2 (0.7) 0.014
Platelet concentrates 5 (1.4) 2 (2.7) 3 (1.1) 0.307
Fresh frozen plasma 19 (5.5) 6 (8.1) 13 (4.8) 0.265
Tranexamic acid 41 (11.8) 21 (28.4) 20 (7.4) < 0.001
  1. Abbreviation: DOAC direct oral anticoagulants, ECs erythrocyte concentrates, IQR interquartile range, PCC prothrombin complex concentrate